Literature DB >> 6143129

Possible hazard of valpromide-carbamazepine combination therapy in epilepsy.

J W Meijer, C D Binnie, R M Debets, J A van Parys, N K de Beer-Pawlikowski.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6143129     DOI: 10.1016/s0140-6736(84)91325-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  11 in total

1.  Valpromide inhibits human epoxide hydrolase.

Authors:  G M Pacifici; M Franchi; C Bencini; A Rane
Journal:  Br J Clin Pharmacol       Date:  1986-09       Impact factor: 4.335

Review 2.  Clinically significant pharmacokinetic drug interactions with carbamazepine. An update.

Authors:  E Spina; F Pisani; E Perucca
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

Review 3.  Pharmacokinetic evaluation of sustained release formulations of antiepileptic drugs. Clinical implications.

Authors:  M Bialer
Journal:  Clin Pharmacokinet       Date:  1992-01       Impact factor: 6.447

4.  Structure-pharmacokinetic relationships in a series of valpromide derivatives with antiepileptic activity.

Authors:  A Haj-Yehia; M Bialer
Journal:  Pharm Res       Date:  1989-08       Impact factor: 4.200

5.  Free concentration of carbamazepine and carbamazepine-10,11-epoxide in children and adults. Influence of age and phenobarbitone co-medication.

Authors:  R Riva; M Contin; F Albani; E Perucca; G Procaccianti; A Baruzzi
Journal:  Clin Pharmacokinet       Date:  1985 Nov-Dec       Impact factor: 6.447

6.  Carbamazepine-viloxazine interaction in patients with epilepsy.

Authors:  F Pisani; A Fazio; G Oteri; E Perucca; M Russo; R Trio; B Pisani; R Di Perri
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-10       Impact factor: 10.154

Review 7.  Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update.

Authors:  L Bertilsson; T Tomson
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

8.  Impairment of carbamazepine-10, 11-epoxide elimination by valnoctamide, a valpromide isomer, in healthy subjects.

Authors:  F Pisani; A Fazio; C Artesi; G Oteri; E Spina; T Tomson; E Perucca
Journal:  Br J Clin Pharmacol       Date:  1992-07       Impact factor: 4.335

Review 9.  Free drug concentration monitoring in clinical practice. Rationale and current status.

Authors:  C K Svensson; M N Woodruff; J G Baxter; D Lalka
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

10.  Effect of valpromide on the pharmacokinetics of carbamazepine-10, 11-epoxide.

Authors:  F Pisani; A Fazio; G Oteri; E Spina; E Perucca; L Bertilsson
Journal:  Br J Clin Pharmacol       Date:  1988-05       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.